House Panel Holds Hearing on Self-Referral
July 1st 1995WASHINGTON--The House of Representatives Ways and Means Subcommittee on Health heard opinions on what sort of final regulations should be issued concerning the recently expanded self-referral laws: namely, enforce the bill as written (HCFA's view) or add major exceptions to the bill (the AMA's view).
Mitoguazone Appears Promising in HIV-Associated Refractory NHL
July 1st 1995ASCO LOS ANGELES--In a multicenter phase II study of mitogua-zone (MGBG) in relapsed or refractory AIDS-related non-Hodgkin's lymphoma (NHL), more than one quarter of patients responded to the drug, and all of the complete responders experienced an increase in their CD4 counts, Alexandra M. Levine, MD, reported at ASCO.
Smoking Cessation Guidelines Should Include Smokeless Tobacco
July 1st 1995Increasing numbers of Americans are using smokeless tobacco, because they think it is a safe alternative to cigarettes. Upcoming federal guidelines on smoking prevention and cessation should include information about the health risks
NCI Committed to Increasing Minority Participation in Clinical Trials
July 1st 1995BETHESDA, Md--Acting NCI Director Edward Sondik announced that the institute is committed to increasing participation of minorities in clinical trials. However, cancer researchers have had only limited success in this effort, he said.
Addition of Radiation Therapy to Surgery Nearly Doubles Survival of Rectal Cancer Patients
July 1st 1995adiation therapy before surgery increases survival without increasing long-term complications for patients with rectal cancer, according to a 10-year study at Tufts University presented at the recent meeting of the American Radium Society. Resection
Cord Blood is Used as Source of Stem Cells for Pediatric Transplantation
July 1st 1995SAN DIEGO, Calif--Investigators have demonstrated that umbilical cord blood contains cells capable of instituting long-term, donor-derived hematopoiesis--with a very low probability of producing graft-versus-host disease (GVHD), John E. Wagner, MD, said at a conference sponsored by the University of California, San Diego Cancer Center and the UCSD School of Medicine.
Neighboring Western States Have Highest, Lowest Smoking-Attributable Mortality
July 1st 1995New statistics from the Centers for Disease Control and Prevention (CDC) show Utah and Nevada (so close in proximity, so distant in life-style) at the top and bottom, respectively, of a ranking of states by smoking-related mortality (see table). The
Cost Utility Study Shows Value of Aggressive Antiemetic Use
July 1st 1995LONG BEACH, Calif-Cost utility studies are in their infancy and can yield very different results if incorrect assumptions about utility scores are made. For example, two different analyses of the same cost utility data suggested that the cost of a 5-HT3 antagonist in patients receiving emetic chemotherapy is either $4,000 per quality-adjusted life year (QALY), or 10 times that much.
'Smarter' Drugs May Inhibit Tumor Growth By Blocking Angiogenesis or Matrix Metalloproteinase
July 1st 1995TORONTO, Canada--Available cancer drugs have had little specificity, destroying both cancer cells and normal cells. Now, says Robert Kerbel, PhD, of Sunnybrook Health Science Centre, University of Toronto, "we have the potential to design 'smarter' drugs to help circumvent the problems of toxicity and resistance." At a media conference at the American Association for Cancer Research (AACR) annual meeting, Dr. Kerbel introduced two researchers who have pioneered development of approaches to inhibit cancer development without harming normal cells.
Radiolabeled-M195 Shows Promise in Myeloid Leukemias
July 1st 1995Radioimmunotherapy with an iodine 131-labeled monoclonal antibody shows promise in two applications in patients with myeloid leukemias: as cytoreductive therapy prior to bone marrow transplantation and for reduction of minimal residual
Psychological Distress Can Be Predicted Early in Cancer Patients
July 1st 1995In a preliminary analysis of a study of more than 800 patients with early-stage cancer, researchers found that those who gave a negative self-appraisal of their situation and their ability to cope were more likely to develop affective disorders during the
Case Reviewers Can Help Resolve Disputes Re: Reimbursement
July 1st 1995HACKENSACK, NJ-- Tough economic times can be blamed for the current game of roulette played by health-care insurers when it comes to coverage of experimental or off-label treatments, said Grace Powers Monaco, JD, director of the Medical Care Ombudsman Program, Medical Care Management Corp. Bethesda, Md. But overeager physicians, patients, and patient advocacy groups must also share some of the blame for the current tug of war, she said.
Study Shows G-CSF To Be Cost Effective
July 1st 1995LONG BEACH, Calif--Using five key indicators of the severity of illness to determine the cost effectiveness of growth factor use, researchers from Blue Cross of Western Pennsylvania found an average cost ratio of about 1:7 for the use of G-CSF (filgrastim, Neupogen) in stage IV breast cancer patients undergoing high-dose chemotherapy/autologous bone marrow transplantation.
Scientists Must Adapt to Reduced NIH Funds
July 1st 1995NEW YORK--How much scientific research is enough? In the best of all possible worlds, an appropriate response might be, "one can never have too much of a good thing." But in the real world, the question must be rephrased: "How much research is possible with the resources available?"
Cancer Care Accounts for 5% of Direct US Health Expenditures
July 1st 1995LONG BEACH, Calif--Neoplasms account for more than 5% of the $675 billion in direct annual US health-care expenditures, Thomas C. Tucker, MPH, said at the 1995 Quality of Life Symposium, sponsored by St. Mary Medical Hospital. This figure, derived from a 1990 National Center for Health Statistics Survey, does not include indirect costs, such as loss of wages, associated with morbidity and mortality.
NIH Establishes New Advisory Committee on Women's Health
July 1st 1995BETHESDA, Md--An Advisory Committee on Research on Women's Health has been chartered to advise the NIH Office of Research on Women's Health. The committee is mandated to offer advice on how to enhance women's health research, ensure that women are included in NIH-supported studies, and improve opportunities for women in biomedical careers.
Only Cost Utility Analyses Include Quality of Life as an Outcome
July 1st 1995LONG BEACH, Calif--Of the different types of economic analyses used in cost studies of medical therapies, only the cost utility analysis takes into account quality of life as an outcome, Jane Weeks, MD, said at the 1995 Quality of Life Symposium, sponsored by St. Mary Medical Center. To understand how this type of analysis works, physicians must add two new measurement units to their vocabulary: "utilities" and "quality-adjusted life years (QALYs)," she said.
Interleukin-11 to Enter Phase III
July 1st 1995CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinant human interleukin-11 (rhIL-11) restored platelets in throm-bocytopenic patients undergoing cancer chemotherapy to the extent that significantly fewer rhIL-11 treated patients required platelet transfusions, compared to placebo.
Colposcopy Cost Effective for Cervical Lesions
July 1st 1995SAN FRANCISCO--For physicians who treat cervical lesions, abandonment of traditional colposcopy for one-step loop excision procedures could lead to excessive treatment and excessive expense, Philip Roland, MD, said at the Society of Gynecologic Oncologists meeting.
Book Review: Surviving Childhood Cancer--A Guide for Families
July 1st 1995Surviving Childhood Cancer, A Guide for Families" meets a tremendous need for easy-to-read, simple-to-understand information about the childhood cancer experience. All too often health-care professionals myopically focus attention and
Board Wants Changes In Intramural Research
July 1st 1995BETHESDA, Md--In an anxiously awaited report, the National Cancer Advisory Board (NCAB) Ad Hoc Working Group on the NCI Intramural Research Program (IRP) made dozens of recommendations for change in the way intramural research is administered and conducted at the Institute (see below).
Medco Research, Inc. and Repligen Corporation Have Agreed to Merge
July 1st 1995CAMBRIDGE, Mass--Repligen Corporation and Medco Research, Inc. (Research Triangle Park, NC) have agreed to merge their two companies. The resulting company's product portfolio will serve three primary markets: cardiovascular disease, oncology, and immunology.
Decision Model Analysis Shows Cost Impact of Growth Factors
July 1st 1995LONG BEACH, Calif--There is no controversy in medical oncology that G-CSF decreases the risk of infection associated with neutropenia in patients receiving cytotoxic chemotherapy. But does it save money? To answer that question, John Glaspy, MD, MPH, and his colleagues at UCLA School of Medicine used a decision analysis model to determine the economic impact of G-CSF given as supportive care.